| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.11 | 0.07 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | -0.056 | 0.07 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.11 | 0.07 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.07 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.092 | 0.08 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.08 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.08 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.08 |